J Compr Ped. 2024 February; 15(1):e139577. https://doi.org/10.5812/jcp-139577.

Published online 2023 December 15. **Research Article**

Potentials of Hyperuricemia and Insulin Levels in Predicting Hypertension in Obese Children: A Cross-sectional Study

Setila Dalili [1], Afagh Hassanzadeh Rad [1], Omid Salkhori [1], Shayan Dabbaghi [1], Mohammad-Mehdi Karambin [1], Hamidreza Badeli [1,*] and Shahin Koohmanaee [1,**]

[1] Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

[*] *Corresponding author*: Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Email: badeli@gums.ac.ir
[**] *Corresponding author*: Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. Email: koohmana@yahoo.com

Received 2023 July 30; **Revised** 2023 October 11; **Accepted** 2023 November 07.

Abstract

Background: Recent studies in humans show that increased uric acid predicts hyperinsulinemia and obesity.
Objectives: Our study aimed to investigate whether hyperuricemia and insulin levels predict hypertension in obese children.
Methods: This analytical cross-sectional study was conducted on the records of 161 obese children aged 5 to 15 years old based on the defined inclusion criteria. Children's blood pressure, height, weight, FBS (fasting blood sugar), HDL (high-density lipoprotein), LDL (low-density lipoprotein), TG (triglyceride), HbA1c (hemoglobin A1c), urine albumin, creatinine, insulin levels, and uric acid were measured. Data were analyzed by SPSS software. The significance level was considered $P < 0.05$.
Results: According to the data obtained from this study, the mean of SBP (systolic blood pressure) and DBP (diastolic blood pressure) in obese children with hyperuricemia was higher than in obese children without hyperuricemia. The average insulin in obese children and hypertension was higher than in obese children without hypertension, especially in males and the age group of 5 - 10 years. The levels of cholesterol and LDL in hypertensive males were higher than in those with hyperuricemia. HDL was higher in children without hyperuricemia than in children with hyperuricemia. The strongest predictors of uric acid were age ($P < 0.001$, $B = 0.183$), HbA1c ($P = 0.014$, $B = 0.255$), and cholesterol ($P = 0.03$, $B = -0.007$), respectively.
Conclusions: Based on this study, there is a relationship between uric acid levels and parameters such as obesity and blood pressure, and the findings showed that increased uric acid predicts hyperinsulinemia and obesity. Therefore, this study indicates that physicians and healthcare workers should consider the level and state of uric acid.

Keywords: Hypertension, Hyperuricemia, Uric Acid, Children, Obesity, Overweight

1. Background

Obesity is defined as a body mass index (BMI) above the 95th percentile (1, 2). It is a chronic disease, and its prevalence is increasing among adults, adolescents, and children due to lifestyle changes, and has now emerged as an epidemic. In the United States, 25% of children are overweight and 11% are obese (3). The highest prevalence rate of childhood obesity has been observed in developed countries. However, it is also increasing in developing countries such as Iran (4, 5). A study estimated the prevalence of childhood obesity in Iran at 4.79% (5). Children who regularly receive more energy than they need are obese. Many different factors cause an imbalance between energy intake and consumption, including genetic factors, incorrect eating habits, reduced physical activity and exercise, and some medications and diseases (6). Obesity in children leads to serious physical and mental complications, including hypertension, hyperuricemia, diabetes, high cholesterol, heart disease, infertility, fatty liver, sleepiness, asthma, musculoskeletal diseases, joint problems, reduced self-confidence, depression, and guilt (7-11).

Hypertension in children is diagnosed when blood pressure is higher than 95% of children of the same age, height, and sex (12, 13). Since children are always growing and developing, it is not possible to define a fixed limit of blood pressure. Hypertension in children has no specific symptoms. Today, due to lifestyle changes that have led to obesity and inactivity in children, blood pressure prevalence is increasing worldwide (14). The cause of

high blood pressure in children can be related to heart, kidney, genetic, and hormonal disorders. Also, children with congenital heart and kidney diseases, premature and underweight, are susceptible to hypertension (15, 16). Children's hypertension may be attributed to sleep apnea, stroke, heart attack, heart failure, and kidney disease (15). Hypertension in children is divided into two categories. Primary hypertension occurs spontaneously and is not caused by a specific disease. Its risk factors include overweight and obesity, family history of hypertension, type 2 diabetes, high cholesterol, and triglycerides. Secondary hypertension develops a specific disease such as chronic kidney disease, heart problems, adrenal gland abnormalities, lupus, or hyperthyroidism (17).

Hyperuricemia is an increase in the uric acid levels of the blood, which occurs as a result of the kidney's inability for its excretion. It is known as uric acid levels above 6 mg/dL in women and above 7 mg/dL in men (18). Natural uric acid levels have antioxidant and protective properties of endothelial cells, while hyperuricemia has anti-oxidant and pro-oxidant properties. These paradoxical roles depend on the microenvironment in different portions of the human body (19, 20). Causes of hyperuricemia include obesity, kidney disease, heredity, alcohol consumption, high-protein foods, gastrointestinal bleeding, diseases such as leukemia, lymphoma, psoriasis, hypertension, and heart failure, drugs such as aspirin, diuretics, tetracycline, corticosteroids, and some antihypertensive drugs (21, 22). Hyperuricemia also leads to complications, including blood pressure, gout, urinary uric acid stones, arthritis, hypersomnia, and platelet changes (23). Some epidemiological studies have reported a relationship between serum uric acid levels and cardiovascular diseases such as hypertension, metabolic syndrome, pre-eclampsia, and diseases of the coronary artery and cerebral artery (24-26).

Considering the complex interaction of serum uric acid, blood pressure, and cardiovascular disease risk factors, it is still under investigation whether uric acid is an independent factor or just an indicator of high blood pressure (27). It has been suggested that various factors such as age (28), height (29), obesity (30), insulin resistance (IR) (31), and renal dysfunction (32), all of which are related to uric acid levels, may play a role in the development of hypertension. Recent studies in humans have also shown that hyperuricemia predicts increased hyperinsulinemia and obesity (33).

2. Objectives

Since previous studies investigated the relationship between one-stage hypertension and uric acid, as well as obesity, uric acid, and hyperinsulinemia, the purpose of our study was to investigate whether hyperuricemia and insulin levels predict hypertension in obese children. We hypothesized that these parameters may help clinicians to predict hypertension.

3. Methods

The current study was an analytical cross-sectional study carried out on the records of obese children aged 5 - 15 years who had been referred to 17 Shahrivar Hospital, Iran, from 2016 to 2017. We performed this study from June 2018 to June 2019. The inclusion criteria were no history of kidney diseases, heart diseases, diabetes, metabolic disorders, neurological disorders, etc. Children who used antihypertensive drugs, uric acid reducers, and obesity treatment were excluded.

Children's blood pressure, height, and weight were measured twice at 5-minute intervals in the traditional way. Before that, the child rested for 30 minutes and did not eat any special food, and one person did the measurements for everyone at a certain time. The measurement of fasting blood sugar (FBS), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), hemoglobin A1c (HbA1c), urine albumin, creatinine (urine Alb. Cr), insulin (Ins) level, and uric acid were done in a fasting state at the hospital laboratory. Body mass index (BMI) was also calculated by relevant formulas based on common tables used to measure children's height and weight. The homeostatic model assessment (HOMA) index to assay insulin resistance was also calculated based on the formula: Insulin $\times$ FBS/ 405.

3.1. Ethical Considerations

This study was approved by the Ethical Committee of Guilan University of Medical Sciences (code: IR.GUMS.REC.1397.067).

3.2. Statistical Analysis

Data were analyzed using IBM SPSS software version 22. Mean and standard deviation were used to describe quantitative data, and percentage was used for qualitative data. Pearson's correlation coefficient was used to check the correlation between blood pressure and uric acid, and because the data were non-parametric, Spearman's correlation test was used. An independent *t*-test was used to compare the mean systolic (SBP) and diastolic blood pressure (DBP) in two groups with and without hyperuricemia. Pearson's correlation coefficient was used to investigate the correlation between uric acid and blood pressure, as well as their relationship with lipid profile, blood sugar, insulin, and BMI. In the case of non-normality of uric acid levels, Mann-Whitney's non-parametric test and Spearman's correlation coefficient were used. Finally, to determine the relationship between hypertension hyperuricemia and blood insulin levels, a

logistic regression model was used after adjusting the background intervention variables in multiple analyses. The significance level of the tests was considered $P < 0.05$.

4. Results

In this study, 161 records of overweight (34.2%) and obese (65.8%) children were examined in terms of uric acid level and its relationship with blood pressure and other blood parameters. The mean ± SD of the age of the studied children was 10.8 ± 2.5. The youngest subject was 5 years old, and the oldest was 15 years old. The majority of children (59%) were over 10 years old. The mean ± SD of the uric acid level of children was 4.5 ± 1.1. The lowest level of uric acid was 1.8, and the highest level was 8.9. The demographic characteristics and laboratory parameters of the research units are presented in Table 1.

Kolmogorov-Smirnov test was used to evaluate the correlation of uric acid level, lipid profile, blood sugar, and SBP and DBP in the studied children. The results showed that the variables did not have a normal distribution ($P < 0.05$). Therefore, the non-parametric Mann-Whitney test and Spearman correlation coefficient were used to compare and assay the correlations.

Table 2 shows the linear correlation of uric acid with SBP, DBP, lipid profile, FBS, Ins, HbA1c, anthropometric indices, HOMA index, and urine albumin and creatinine. The data demonstrated that uric acid significantly correlated with SBP and DBP, age, height, weight, insulin, HbA1c, and HOMA index. It also had an inverse and significant correlation with children's BMI. However, the linear correlation of uric acid with other blood parameters was not significant. On the other hand, SBP significantly correlated with DBP, height, weight, insulin, TG, HOMA index, and children's age. DBP also had a significant positive correlation with height, weight, Ins, TG, HOMA index, and the children's age.

According to the information presented in Table 3, 25% of the studied children who experienced hypertension had hyperuricemia, although this was not significant based on Fisher's test ($P = 0.44$). Also, SBP and DBP were statistically significant in two groups with and without hyperuricemia. The mean SBP and DBP in obese children with hyperuricemia were significantly higher than in obese children without hyperuricemia ($P = 0.014$, $P = 0.023$, respectively). In this table, laboratory parameters are also compared in two groups of children with and without hypertension. The results show that only the children's insulin levels in the two groups with and without hypertension had a statistically significant difference ($P = 0.013$). Therefore, the average level of insulin in children with obesity and hypertension was higher than in obese children without hypertension.

Table 1. Frequency of Demographic Variables and Mean ± SD of Laboratory Parameters of the Studied Units [a]

Variables	Values
BMI	
Overweight	55 (34.2)
Obesity	106 (65.8)
BMI	95.6 ± 4
Sex	
Male	86 (53.4)
Female	75 (46.6)
Age (9)	
5 - 10	66 (41)
11 - 15	95 (59)
Hypertension	
Yes	12 (7.5)
No	149 (92.5)
Hyperuricemia	
Yes	28 (17.4)
No	133 (82.6)
Weight	56.1 ± 18.2
Height	145.4 ± 15.2
SBP	101 ± 10
DBP	65 ± 7
FBS	90 ± 7
HbA1c	5.1 ± 0.9
Insl	17.3 ± 8
TG	122 ± 66
Chol	159 ± 27
LDL	92 ± 21
HDL	43 ± 8
Urine Alb. Cr	8.1 ± 3.8
HOMA	3.86 ± 2.8

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; Ins, insulin; TG, triglyceride; Chol, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Urine Alb. Cr, urine albumin, creatinine; HOMA, homeostatic model assessment.
[a] Values are expressed as Mean ± SD or No. (%).

Table 4 compares the laboratory parameters in two groups with and without hypertension, separated by sex. The data in this table show that only the levels of insulin in males with hypertension were higher than in males without hypertension ($P = 0.019$). In females, as in males, the amount of insulin in the hypertension group was higher than in the non-hypertension group, but this difference was not significant. On the other hand, SBP and

Table 2. Determining the Linear Correlation of Uric Acid Level with Other Parameters in the Studied Children

Variables	Uric Acid	SBP	DBP
SBP			
Correlation coefficient	0.258	1.000	0.744
Sig. (2-tailed)	0.001	0	0.000
DBP			
Correlation coefficient	0.239	0.744	1.000
Sig. (2-tailed)	0.002	> 0.001	0
Age			
Correlation coefficient	0.428	0.421	0.438
Sig. (2-tailed)	> 0.001	> 0.001	> 0.001
Height			
Correlation coefficient	0.345	0.437	0.467
Sig. (2-tailed)	> 0.001	> 0.001	> 0.001
Weight			
Correlation coefficient	0.237	0.423	0.484
Sig. (2-tailed)	> 0.001	> 0.001	> 0.001
BMI			
Correlation coefficient	- 0.188	- 0.138	- 0.037
Sig. (2-tailed)	0.017	0.081	0.643
FBS			
Correlation coefficient	0.132	- 0.004	0.041
Sig. (2-tailed)	0.095	0.964	0.601
HbA1c			
Correlation coefficient	0.246	0.096	0.151
Sig. (2-tailed)	0.002	0.236	0.061
Insl			
Correlation coefficient	0.172	0.211	0.193
Sig. (2-tailed)	0.033	0.009	0.017
TG			
Correlation coefficient	0.091	0.216	0.160
Sig. (2-tailed)	0.253	0.006	0.042
Chol			
Correlation coefficient	0.041	0.182	0.107
Sig. (2-tailed)	0.604	0.021	0.176
LDL			
Correlation coefficient	- 0.032	0.128	0.097
Sig. (2-tailed)	0.685	0.106	0.223
HDL			
Correlation coefficient	- 0.061	- 0.034	- 0.108
Sig. (2-tailed)	0.441	0.671	0.173
Urine Alb. Cr			
Correlation coefficient	- 0.025	- 0.068	0.055
Sig. (2-tailed)	0.781	0.448	0.542
HOMA			
Correlation coefficient	0.222	0.200	0.201
Sig. (2-tailed)	0.006	0.013	0.013

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; Ins, insulin; TG, triglyceride; Chol, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; urine Alb. Cr, urine albumin, creatinine; HOMA, homeostatic model assessment.

DBP were statistically significantly different in two groups of obese females with and without hyperuricemia (P = 0.024, P = 0.027, respectively). These values were higher in obese males with hyperuricemia than in those without hyperuricemia, but it was not statistically significant. In the male group, only cholesterol and LDL were statistically significant (P = 0.029, P = 0.034, respectively). It is noteworthy that the levels of cholesterol and LDL in the obese male group without hyperuricemia were higher than in the group with hyperuricemia.

Table 3. Comparative Investigation of Blood Pressure and Other Variables in Two Groups with and Without Hyperuricemia in the Studied Children

Variables	Hyperuricemia		P-Value
	Yes	No	
Hypertension, No. (%)			0.44
Yes	3 (25)	9 (75)	
No	25 (16.8)	124 (83.2)	
Hyperuricemia, Mean ± SD			
SBP	105.9 ± 9.6	100.5 ± 9.7	0.014 [a]
DBP	67.3 ± 7	64.1 ± 7.1	0.023 [a]
FBS	89.2 ± 7.2	90 ± 6.7	0.717
HbA1c	5.6 ± 1.4	5.1 ± 0.7	0.164
Ins	18.5 ± 7.8	17 ± 8	0.292
TG	120.1 ± 61.3	122 ± 67.6	0.913
Chol	154.7 ± 28.6	160 ± 26.2	0.231
LDL	89.4 ± 18.6	92 ± 21.5	0.528
HDL	41.8 ± 8.3	43.2 ± 8.1	0.216
Urine Alb. Cr	9.1 ± 4.9	7.9 ± 3.5	0.351
HOMA	4.1 ± 1.7	3.9 ± 2.1	0.231
Hypertension, Mean ± SD			
SBP	-	-	-
DBP	-	-	-
FBS	87.6 ± 6.8	90.1 ± 6.8	0.321
HbA1c	5.1 ± 0.6	5.2 ± 0.9	0.791
Ins	25 ± 11.2	16.7 ± 7.4	0.013 [a]
TG	140.9 ± 66.2	120.1 ± 66.3	0.138
Chol	157.9 ± 37.5	159.2 ± 25.7	0.88
LDL	89.4 ± 27.4	91.7 ± 20.5	0.748
HDL	40.2 ± 5.2	43.2 ± 8.3	0.301
Urine Alb.Cr	9.5 ± 5	8 ± 3.7	0.336
HOMA	5.1 ± 2.5	3.8 ± 2	0.064

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; Ins, insulin; TG, triglyceride; Chol, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; urine Alb. Cr, urine albumin, creatinine; HOMA, homeostatic model assessment.
[a] Significant P values.

The information in Table 5 shows that there is a significant difference in the amount of insulin and HOMA index in the age group of 5 - 10 years between the two groups with and without hypertension (P = 0.006, P = 0.006; respectively). Insulin levels and HOMA index are lower in children without hypertension compared to children with hypertension. Also, only HDL in obese children aged 5 - 10 had a significant difference between the two groups with and without hyperuricemia (P = 0.042), so the amount of HDL in children without hyperuricemia was higher than in children with hyperuricemia.

In multivariate analysis, a multivariate linear regression model was used to investigate the relationship between uric acid and blood pressure in obese children by adjusting the effects of other investigated variables. As can be seen in Table 6, based on the results of this model, although the effect of SBP and DBP was significantly related to hyperuricemia in univariate analysis, it was not considered a strong predictor in multivariate analysis based on the linear regression model ($P > 0.05$). Finally, the strongest predictors related to uric acid were age ($P < 0.001$, B = 0.183), HbA1c (P = 0.014, B = 0.255), and cholesterol (P = 0.03, B = -0.007). It was found that based

Table 4. Comparison of the Studied Variables in Two Groups with and Without Hypertension and with and Without Hyperuricemia Separated by Sex

Variables	Male		P-Value	Female		P-Value
	Yes	No		Yes	No	
Hypertension, Mean ± SD						
FBS	89 ± 5.7	91 ± 7.1	0.628	86.2 ± 8	89 ± 6.4	0.44
HbA1c	5.2 ± 0.8	5 ± 0.7	0.362	4.9 ± 0.4	5.4 ± 1	0.136
Ins	27 ± 9.8	16.3 ± 7.4	0.019 [a]	23.4 ± 12.9	17.2 ± 7.4	0.237
TG	155 ± 80.9	119.3 ± 62	0.127	126.8 ± 51.4	121.1 ± 71.4	0.564
Chol	176 ± 34.4	158 ± 27.3	0.164	139.8 ± 33.7	160.5 ± 23.8	0.080
LDL	100.5 ± 26.7	91.5 ± 20.5	0.236	78.3 ± 25.2	91.9 ± 20.6	0.109
HDL	41.7 ± 6.1	42.1 ± 8.1	0.966	38.7 ± 4.2	44.3 ± 8.5	0.085
Urine Alb.Cr	6.9 ± 2.4	8 ± 3.7	0.481	12.1 ± 5.7	7.9 ± 3.8	0.071
HOMA	5.4 ± 2	3.8 ± 2.3	0.070	5 ± 2.9	3.8 ± 1.7	0.370
Hyperuricemia, Mean ± SD						
SBP	107.5 ± 12.7	101.7 ± 9.2	0.131	104.7 ± 6.7	99 ± 10.2	0.024 [a]
DBP	68.3 ± 8.3	65.1 ± 7	0.161	66.6 ± 6	62.7 ± 7.1	0.027 [a]
FBS	87.3 ± 8	91.5 ± 6.7	0.121	90.7 ± 6.4	88.3 ± 6.5	0.166
HbA1c	5.3 ± 1.4	5 ± 0.6	0.671	5.7 ± 1.5	5.2 ± 0.8	0.262
Insl	19.4 ± 9.1	16.6 ± 7.8	0.402	17.8 ± 7	17.7 ± 8.4	0.611
TG	118.9 ± 79.6	122.3 ± 61.3	0.270	121.1 ± 46	121.7 ± 75.2	0.526
Chol	144.4 ± 33.7	161.7 ± 26.4	0.029 [a]	162.4 ± 22.3	157.8 ± 25.9	0.526
LDL	80.6 ± 19.5	94 ± 20.7	0.034 [a]	95.9 ± 15.4	89.5 ± 22.3	0.260
HDL	40.3 ± 8	42.4 ± 8	0.208	42.9 ± 8.5	44.1 ± 8.3	0.464
Urine Alb.Cr	9.7 ± 4.8	7.7 ± 3.3	0.187	8.7 ± 5.1	8.1 ± 3.8	0.972
HOMA	3.8 ± 1.7	3.9 ± 2.4	0.835	4.3 ± 1.7	3.8 ± 1.9	0.218

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; Ins, insulin; TG, triglyceride; Chol, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Urine Alb. Cr, urine albumin, creatinine; HOMA, homeostatic model assessment.
[a] Significant P-values.

on the overall Scatterplot, these three factors predict 22.6% of uric acid changes (R = 0.226). Of these, based on the partial regression plots below, the share of age was 16.8%, the share of cholesterol was 1.5%, and the share of HbA1c was 4.5%.

5. Discussion

The results of the present study showed that the mean SBP and DBP in obese children with hyperuricemia were higher than in obese children without hyperuricemia, especially in females. The average insulin in children with obesity and hypertension was higher than in obese children without hypertension, especially in males and the age group of 5 - 10 years. The levels of cholesterol and LDL in the obese male group without hyperuricemia were higher than in the group with hyperuricemia. Also, the levels of HDL in 5 - 10-year-old children without hyperuricemia were higher than in children with hyperuricemia. Although the effect of SBP and DBP was related to hyperuricemia in univariate analysis, it was not considered a strong predictor in multivariate analysis. The strongest predictors related to uric acid were age, HbA1c, and cholesterol, respectively.

One of the main causes of hyperuricemia in children is obesity, which is associated with disorders such as hypertension, dyslipidemia, insulin resistance, and chronic kidney diseases (34-36). It is suggested that hyperuricemia can be considered a predictor of cardiometabolic diseases in early childhood (11, 37, 38). Consistent with our study, in a number of studies, the association of hyperuricemia with hypertension has been stated in adults and children (25, 39-41). It has been demonstrated that each 1 mg/dL increase in uric acid level increases the risk of pre-hypertension or hypertension by at least 50% over normotensive children

Table 5. Comparison of the Studied Variables in Two Groups with and Without Hypertension and with and Without Hyperuricemia Separated by Age

Variables	5 - 10		P-Value	11 - 15		P-Value
	Yes	No		Yes	No	
Hypertension, Mean ± SD						
FBS	88.3 ± 9.3	88.3 ± 6.2	0.808	87.3 ± 5.9	91.4 ± 6.9	0.121
HbA1c	5.1 ± 0.7	5 ± 0.7	0.900	5 ± 0.6	5.3 ± 1	0.714
Ins	30.4 ± 8.7	14.5 ± 6.9	0.006 [a]	21.9 ± 11.8	18.2 ± 7.4	0.438
TG	106.5 ± 27.1	110.8 ± 46.9	0.646	158.1 ± 74.6	126.8 ± 76.8	0.086
Chol	147.8 ± 22.6	153.5 ± 24.6	0.707	163 ± 43.7	163.2 ± 25.8	0.904
LDL	89 ± 25.1	88.8 ± 20.9	0.840	89.6 ± 30.1	93.8 ± 20	0.881
HDL	40.3 ± 2.6	43.1 ± 8.4	0.705	40.1 ± 6.3	43.2 ± 8.3	0.349
Urine Alb.Cr	11.4 ± 6.2	8.3 ± 3.4	0.169	8.3 ± 1.4	7.8 ± 3.2	0.815
HOMA	6.6 ± 2	3.2 ± 1.5	0.006 [a]	4.2 ± 2.3	3.4 ± 2.2	0.771
Hyperuricemia, Mean ± SD						
SBP	101.3 ± 14.4	97.1 ± 9.2	0.650	106.7 ± 8.8	103.5 ± 9.1	0.155
DBP	61.3 ± 6.3	61.9 ± 6.1	0.806	68.3 ± 6.7	66 ± 7.4	0.137
FBS	88 ± 6.9	88.7 ±6.4	0.969	89.4 ± 7.4	91.5 ± 6.7	0.317
HbA1c	4.7 ± 0.5	5 ± 0.7	0.311	5.7 ± 1.5	5.1 ± 0.7	0.107
Insl	17 ± 14	15.5 ± 7.6	0.692	18.7 ± 6.7	18.4 ± 8.2	0.482
TG	124.3 ±76.1	109.7 ± 44.1	0.928	119.5 ± 60.4	132.8 ± 81.6	0.482
Chol	145.5 ± 19.2	153.6 ± 24.7	0.475	156.3 ± 29.9	165.5 ± 26.3	0.160
LDL	82.8 ± 5.2	89.2 ± 21.5	0.806	90.5 ± 19.9	94.4 ± 21.3	0.381
HDL	36.8 ± 1.4	43.3 ± 8.2	0.042 [a]	42.6 ± 8.5	43.1 ± 8.1	0.630
Urine Alb.Cr	11.1 ± 6.5	8.3 ± 3.4	0.308	8.7 ± 4.6	7.5 ± 2.6	0.517
HOMA	3.7 ± 3.1	3.4 ± 1.7	0.775	4.2 ± 1.5	3.4 ± 2.4	0.453

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; Ins, insulin; TG, triglyceride; Chol, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Urine Alb. Cr, urine albumin, creatinine; HOMA, homeostatic model assessment.
[a] Significant P-values.

(22). Hyperuricemia can reduce nitric oxide levels in the endothelium, increase oxidative stress, and activate the renin-angiotensin system, and in this way, it is considered a causal factor for hypertension (42). A study showed that a long-term implementation of healthy lifestyle changes and a decrease in serum uric acid levels among a group of children at risk of cardiovascular disease lead to changes in blood pressure (43). In the study of Ozalp Kizilay et al. in 2019, no relationship was found between hyperuricemia and hypertension. They attributed this to the observation that the duration of exposure to uric acid and the inflammation and oxidative stress caused by it had been probably short (37). In addition, the present study showed that blood pressure was higher in obese females with hyperuricemia compared to males. In its explanation, we can mention the issue of puberty and hormones because girls' puberty happens earlier and at a younger age. The studies by Sebekova et al. and Lin et al. in 2020 were in line with our findings that showed hyperuricemia and hypertension were greater in females than in males (44, 45).

A section of our study showed a significant and inverse relationship between uric acid and children's BMI. Contrary to our study, several studies have shown that hyperuricemia is not related to BMI, but the distribution pattern of visceral body fat plays a more important role (37, 46-48). For example, the study by Ozalp Kizilay et al. showed that an increase in the wrist resulted in an increase in uric acid in children. Hip ratio and wrist circumference were also influential, but BMI was not (37). Another study by Sebekova et al.2020 showed that hyperuricemia in obese and Overweight adolescents had a direct and significant relationship with BMI (44, 49). This difference may be attributed to the age of the studied children. Furthermore, in school children with hypertension, significantly higher records of age, height,

Table 6. Multivariate Analysis to Investigate the Relationship Between Uric Acid and Blood Pressure in Obese Children by Adjusting the Effects of Other Investigated Variables

Model	Unstandardized Coefficients		Sig. [a]	95.0% Confidence Interval for B	
	B	Std. Error		Lower Bound	Upper Bound
1					
Constant	2.565	0.426	0.000	1.721	3.409
Age	0.193	0.039	0.000	0.117	0.270
2					
Constant	1.625	0.590	0.007	0.458	2.793
Age	0.168	0.040	0.000	0.089	0.246
HbA1c	0.235	0.104	0.025	0.030	0.441
3					
Constant	2.550	0.717	0.001	1.130	3.969
Age	0.183	0.040	0.001	0.104	0.261
HbA1c	0.255	0.103	0.014	0.052	0.458
Chol	- 0.007	0.003	0.030	- 0.014	- 0.001

[a] Significant P-values.

weight, and BMI were observed (50).

The findings of the present study confirmed a significant negative correlation between uric acid and HDL, and HDL levels were low in 5 - 10-year-old children with hyperuricemia. Also, cholesterol and LDL levels were higher in the obese males without hyperuricemia. In this regard, several studies have shown that high uric acid is associated with a decrease in HDL and an increase in serum cholesterol and triglycerides (37, 41, 49, 51, 52). The cause of dyslipidemia in hyperuricemia can be related to inflammation and vascular damage that induces the risk of atherosclerosis. Valle et al. also showed a correlation between uric acid levels and inflammatory biomarkers and endothelial dysfunction in obese children close to puberty. Also, this negative correlation between HDL and uric acid was confirmed (53).

The present results indicated a significant relationship between uric acid and insulin and the HOMA index. In line with these pathological findings, several studies confirmed that hyperuricemia is a predictor of IR and hyperinsulinemia and, subsequently, increases the HOMA index (37, 51, 54, 55). It has been demonstrated that with each 1 mg/dL increase in uric acid, the risk of IR increases by 91%. The possible mechanism for that is decreased renal secretion and increased production by the hexose monophosphate shunt (56). Also, hyperuricemia-mediated endothelial dysfunction can decrease insulin uptake through low blood flow in peripheral tissues (57). On the other hand, with the increase in insulin resistance, the blood glucose level increases and causes hemoglobin to become glycosylated, and thus, the blood HbA1c level increases, which indicates poor blood sugar control in the studied children.

Considering that changes in uric acid levels occur gradually during development, it is natural that the amount of uric acid depends on age, as seen in our study. In line with this finding of ours, Kumar and colleagues 2021 showed that hyperuricemia was more common in older children (58).

Another important finding of the present study was that the level of insulin and HOMA index increased significantly in obese children with hypertension, especially in males and the age group of 5 - 10 years. Some studies confirmed an increase in HOMA index, IR, and hyperinsulinemia in obese and hypertension children and adolescents (59, 60). More than three decades ago, it was demonstrated that hyperinsulinemia and IR play an important role in increasing BP associated with obesity, called “syndrome X”. Hyperinsulinemia can increase BP through increases in sympathetic nervous system activity and renal sodium retention. Also, hyperinsulinemia-induced hyperglycemia and dyslipidemia caused vascular and kidney injury (61). In the completion of our results, Galipeau et al. observed that hypertension was higher in male rats with hyperinsulinemia compared to female ones. They justified this by the fact that female rats are less susceptible to the vasoconstrictor TxA2 (62). Furthermore, Takizawa et al. revealed that in human hypertension-associated hyperinsulinemia is higher in males than females (63). Such sex differences may be related to female sex hormones that protect against the adverse cardiovascular effects of hyperinsulinemia. Also, it may be related to differences in adipose distribution or lipid metabolism,

or both mechanisms.

Among the limitations of the present study are the small statistical population and the lack of comparison of the obtained data with a control group. Since the current study was a cross-sectional study, conducting controlled studies with a larger statistical population is recommended.

5.1. Conclusions

In summary, there is a relationship between uric acid levels and parameters such as obesity, blood pressure, and insulin. The prevalence of hyperuricemia in overweight and obese children is high, which shows that hyperuricemia can be a predictor of hyperinsulinemia and obesity. Therefore, this study can raise the issue that the status of uric acid should be taken into consideration by physicians and the healthcare system.

Footnotes

Authors' Contribution: Study design: HB, AHR, SD, OS, SD; Gathering data: SHD, ShK, MMK; Data analysis: AHR, OS, SD, ShK, MMK; Drafting manuscript: HB, AHR, MMK, SD, OS. Revising the manuscript: HB, AHR, SHK, SD, OS, SD.

Conflict of Interests: Setila Dalili and Shahin Koohmanaee are the reviewers.

Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to ethical considerations.

Ethical Approval: This study has been approved by the ethical committee of Guilan University of Medical Sciences (code: IR.GUMS.REC.1397.067).

Funding/Support: This study was part of an MD thesis approved by Guilan University of Medical Sciences, which was not financially supported.

References

1. Flegal KM, Wei R, Ogden C. Weight-for-stature compared with body mass index-for-age growth charts for the United States from the Centers for Disease Control and Prevention. *Am J Clin Nutr*. 2002;**75**(4):761–6. [PubMed ID: 11916765]. https://doi.org/10.1093/ajcn/75.4.761.
2. Himes JH, Dietz WH. Guidelines for overweight in adolescent preventive services: recommendations from an expert committee. The Expert Committee on Clinical Guidelines for Overweight in Adolescent Preventive Services. *Am J Clin Nutr*. 1994;**59**(2):307–16. [PubMed ID: 8310979]. https://doi.org/10.1093/ajcn/59.2.307.
3. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. *N Engl J Med*. 1997;**337**(13):869–73. [PubMed ID: 9302300]. https://doi.org/10.1056/NEJM199709253371301.
4. James PT. Obesity: the worldwide epidemic. *Clin Dermatol*. 2004;**22**(4):276–80. [PubMed ID: 15475226]. https://doi.org/10.1016/j.clindermatol.2004.01.010.
5. Kelishadi R, Ardalan G, Gheiratmand R, Majdzadeh R, Hosseini M, Gouya MM, et al. Thinness, overweight and obesity in a national sample of Iranian children and adolescents: CASPIAN Study. *Child Care Health Dev*. 2008;**34**(1):44–54. [PubMed ID: 18171443]. https://doi.org/10.1111/j.1365-2214.2007.00744.x.
6. Ruxton C. Obesity in children. *Nurs Stand*. 2004;**18**(20):47–52. quiz 54-5. [PubMed ID: 14976705]. https://doi.org/10.7748/ns2004.01.18.20.47.c3537.
7. Alemzadeh R, Rising R, Cedillo M, Lifshitz F. Obesity in Children. *Pediatric Endocrinology*. Marcel Dekker; 2003. p. 1–36. https://doi.org/10.3109/9781439808948-2.
8. Makkes S, Renders CM, Bosmans JE, van der Baan-Slootweg OH, Seidell JC. Cardiometabolic risk factors and quality of life in severely obese children and adolescents in The Netherlands. *BMC Pediatr*. 2013;**13**:62. [PubMed ID: 23607651]. [PubMed Central ID: PMC3639189]. https://doi.org/10.1186/1471-2431-13-62.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). *J Hypertens*. 2007;**25**(6):1105–87. [PubMed ID: 17563527]. https://doi.org/10.1097/HJH.0b013e3281fc975a.
10. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. *Diabetes Care*. 2008;**31**(2):361–2. [PubMed ID: 17977935]. https://doi.org/10.2337/dc07-1276.
11. Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. *Eur J Intern Med*. 2016;**29**:3–8. [PubMed ID: 26703429]. [PubMed Central ID: PMC4826346]. https://doi.org/10.1016/j.ejim.2015.11.026.
12. Jones DP, Richey PA, Alpert BS. Comparison of ambulatory blood pressure reference standards in children evaluated for hypertension. *Blood Press Monit*. 2009;**14**(3):103–7. [PubMed ID: 19433980]. [PubMed Central ID: PMC2755509]. https://doi.org/10.1097/MBP.0b013e32832ce11e.
13. Sinaiko AR. Hypertension in children. *N Engl J Med*. 1996;**335**(26):1968–73. [PubMed ID: 8960478]. https://doi.org/10.1056/NEJM199612263352607.
14. Song P, Zhang Y, Yu J, Zha M, Zhu Y, Rahimi K, et al. Global prevalence of hypertension in children: A systematic review and meta-analysis. *JAMA Pediatr*. 2019;**173**(12):1154–63. [PubMed ID: 31589252]. [PubMed Central ID: PMC6784751]. https://doi.org/10.1001/jamapediatrics.2019.3310.
15. Thaker N. Hypertension in children. *Apollo Medicine*. 2011;**8**(4):248–60. https://doi.org/10.1016/s0976-0016(11)60001-x.
16. Carter J. Hypertension in children. *S Afr Fam Pract*. 1987;**8**(5).
17. Feig D. Hypertension in Children. In: Deepa HC, Rudolph PV, editors. *Clinician's Manual of Pediatric Nephrology*. 2011. p. 357–77. https://doi.org/10.1142/9789814317887_0031.
18. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. *Hypertension*. 2005;**45**(1):28–33. [PubMed ID: 15569852]. https://doi.org/10.1161/01.HYP.0000150784.92944.9a.
19. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. *J Cardiol*. 2012;**59**(3):235–42. [PubMed ID: 22398104]. https://doi.org/10.1016/j.jjcc.2012.01.013.
20. Kang DH, Ha SK. Uric acid puzzle: Dual role as anti-oxidantand pro-oxidant. *Electrolyte Blood Press*. 2014;**12**(1):1–6. [PubMed ID: 25061467]. [PubMed Central ID: PMC4105384]. https://doi.org/10.5049/EBP.2014.12.1.1.
21. Feig DI. Uric acid and hypertension. *Semin Nephrol*. 2011;**31**(5):441–6. [PubMed ID: 22000651]. https://doi.org/10.1016/j.semnephrol.2011.08.008.

22. Viazzi F, Antolini L, Giussani M, Brambilla P, Galbiati S, Mastriani S, et al. Serum uric acid and blood pressure in children at cardiovascular risk. *Pediatrics*. 2013;**132**(1):e93–9. [PubMed ID: 23776119]. https://doi.org/10.1542/peds.2013-0047.
23. Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. *J Clin Hypertens (Greenwich)*. 2012;**14**(6):346–52. [PubMed ID: 22672087]. [PubMed Central ID: PMC8108870]. https://doi.org/10.1111/j.1751-7176.2012.00662.x.
24. Alper AB, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. *Hypertension*. 2005;**45**(1):34–8. [PubMed ID: 15569853]. https://doi.org/10.1161/01.HYP.0000150783.79172.bb.
25. Loeffler LF, Navas-Acien A, Brady TM, Miller ER, Fadrowski JJ. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. *Hypertension*. 2012;**59**(4):811–7. [PubMed ID: 22353609]. [PubMed Central ID: PMC3700426]. https://doi.org/10.1161/HYPERTENSIONAHA.111.183244.
26. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension*. 2003;**42**(3):247–52. [PubMed ID: 12900431]. [PubMed Central ID: PMC1800942]. https://doi.org/10.1161/01.HYP.0000085858.66548.59.
27. Viazzi F, Leoncini G, Ratto E, Pontremoli R. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. *J Clin Hypertens (Greenwich)*. 2006;**8**(7):510–8. [PubMed ID: 16849905]. [PubMed Central ID: PMC8109461]. https://doi.org/10.1111/j.1524-6175.2006.04755.x.
28. Galescu O, George M, Basetty S, Predescu I, Mongia A, Ten S, et al. Blood pressure over height ratios: Simple and accurate method of detecting elevated blood pressure in children. *Int J Pediatr*. 2012;**2012**:253497. [PubMed ID: 22577400]. [PubMed Central ID: PMC3332207]. https://doi.org/10.1155/2012/253497.
29. Liang Y, Mi J. Pubertal hypertension is a strong predictor for the risk of adult hypertension. *Biomed Environ Sci*. 2011;**24**(5):459–66. [PubMed ID: 22108410]. https://doi.org/10.3967/0895-3988.2011.05.002.
30. Genovesi S, Antolini L, Giussani M, Pieruzzi F, Galbiati S, Valsecchi MG, et al. Usefulness of waist circumference for the identification of childhood hypertension. *J Hypertens*. 2008;**26**(8):1563–70. [PubMed ID: 18622233]. https://doi.org/10.1097/HJH.0b013e328302842b.
31. Genovesi S, Brambilla P, Giussani M, Galbiati S, Mastriani S, Pieruzzi F, et al. Insulin resistance, prehypertension, hypertension and blood pressure values in paediatric age. *J Hypertens*. 2012;**30**(2):327–35. [PubMed ID: 22179078]. https://doi.org/10.1097/HJH.0b013e32834e4aaa.
32. VanDeVoorde RG, Mitsnefes MM. Hypertension and CKD. *Adv Chronic Kidney Dis*. 2011;**18**(5):355–61. [PubMed ID: 21896377]. https://doi.org/10.1053/j.ackd.2011.03.003.
33. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension*. 2003;**42**(4):474–80. [PubMed ID: 12953019]. https://doi.org/10.1161/01.HYP.0000091371.53502.D3.
34. Kubota M. Hyperuricemia in children and adolescents: Present knowledge and future directions. *J Nutr Metab*. 2019;**2019**:3480718. [PubMed ID: 31192008]. [PubMed Central ID: PMC6525889]. https://doi.org/10.1155/2019/3480718.
35. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care*. 2009;**32**(9):1737–42. [PubMed ID: 19549729]. [PubMed Central ID: PMC2732137]. https://doi.org/10.2337/dc09-0288.
36. Ishizaka N, Ishizaka Y, Toda A, Tani M, Koike K, Yamakado M, et al. Changes in waist circumference and body mass index in relation to changes in serum uric acid in Japanese individuals. *J Rheumatol*. 2010;**37**(2):410–6. [PubMed ID: 20032099]. https://doi.org/10.3899/jrheum.090736.
37. Ozalp Kizilay D, Sen S, Ersoy B. Associations between serum uric acid concentrations and cardiometabolic risk and renal injury in obese and overweight children. *J Clin Res Pediatr Endocrinol*. 2019;**11**(3):262–9. [PubMed ID: 30759960]. [PubMed Central ID: PMC6745466]. https://doi.org/10.4274/jcrpe.galenos.2018.2019.0241.
38. Mangge H, Zelzer S, Puerstner P, Schnedl WJ, Reeves G, Postolache TT, et al. Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. *Obesity (Silver Spring)*. 2013;**21**(1):E71–7. [PubMed ID: 23401248]. https://doi.org/10.1002/oby.20061.
39. Stewart DJ, Langlois V, Noone D. Hyperuricemia and hypertension: Links and risks. *Integr Blood Press Control*. 2019;**12**:43–62. [PubMed ID: 31920373]. [PubMed Central ID: PMC6935283]. https://doi.org/10.2147/IBPC.S184685.
40. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? *Curr Hypertens Rep*. 2013;**15**(3):175–81. [PubMed ID: 23588856]. [PubMed Central ID: PMC3736857]. https://doi.org/10.1007/s11906-013-0344-5.
41. Foster C, Smith L, Alemzadeh R. Excess serum uric acid is associated with metabolic syndrome in obese adolescent patients. *J Diabetes Metab Disord*. 2020;**19**(1):535–43. [PubMed ID: 32548073]. [PubMed Central ID: PMC7270295]. https://doi.org/10.1007/s40200-020-00507-2.
42. Cortese F, Giordano P, Scicchitano P, Faienza MF, De Pergola G, Calculli G, et al. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects. *Vascul Pharmacol*. 2019;**120**:106565. [PubMed ID: 31152976]. https://doi.org/10.1016/j.vph.2019.106565.
43. Viazzi F, Rebora P, Giussani M, Orlando A, Stella A, Antolini L, et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. *Hypertension*. 2016;**67**(5):934–40. [PubMed ID: 27021006]. https://doi.org/10.1161/HYPERTENSIONAHA.115.06852.
44. Sebekova K, Gurecka R, Podracka L. Asymptomatic hyperuricemia associates with cardiometabolic risk indicators in overweight/obese but not in lean adolescents. *Diabetes Metab Syndr Obes*. 2020;**13**:3977–92. [PubMed ID: 33149637]. [PubMed Central ID: PMC7603647]. https://doi.org/10.2147/DMSO.S267123.
45. Lin YK, Lin YP, Lee JT, Lin CS, Wu TJ, Tsai KZ, et al. Sex-specific association of hyperuricemia with cardiometabolic abnormalities in a military cohort: The CHIEF study. *Medicine (Baltimore)*. 2020;**99**(12). e19535. [PubMed ID: 32195957]. [PubMed Central ID: PMC7220045]. https://doi.org/10.1097/MD.0000000000019535.
46. Luciano R, Shashaj B, Spreghini M, Del Fattore A, Rustico C, Wietrzykowska Sforza R, et al. Percentiles of serum uric acid and cardiometabolic abnormalities in obese Italian children and adolescents. *Ital J Pediatr*. 2017;**43**(1):3. [PubMed ID: 28049502]. [PubMed Central ID: PMC5209902]. https://doi.org/10.1186/s13052-016-0321-0.
47. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. *Circulation*. 2007;**115**(19):2526–32. [PubMed ID: 17470699]. https://doi.org/10.1161/CIRCULATIONAHA.106.657627.
48. Tershakovec AM, Kuppler KM, Zemel BS, Katz L, Weinzimer S, Harty MP, et al. Body composition and metabolic factors in obese children and adolescents. *Int J Obes Relat Metab Disord*. 2003;**27**(1):19–24. [PubMed ID: 12532149]. https://doi.org/10.1038/sj.ijo.0802185.
49. Thomazini F, de Carvalho BS, de Araujo PX, Franco MDC. High uric acid levels in overweight and obese children and their relationship with cardiometabolic risk factors: what is missing in this puzzle? *J Pediatr Endocrinol Metab*. 2021;**34**(11):1435–41. [PubMed ID: 34331525]. https://doi.org/10.1515/jpem-2021-0211.
50. Badeli H, Hassankhani A, Naeemi Z, Hosseinzadeh S, Mehrabi S, Pourkarimi M, et al. Prevalence of hypertension and obesity-related hypertension in urban school-aged children in rasht. *Iran J Kidney Dis*. 2016;**10**(6):364–8. [PubMed ID: 27903995].
51. Liang S, Zhang D, Qi J, Song X, Xue J. Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents. *Sci Rep*. 2018;**8**(1):7931. [PubMed ID: 29785038]. [PubMed Central ID: PMC5962610]. https://doi.org/10.1038/s41598-018-26276-w.
52. Han GM, Gonzalez S, DeVries D. Combined effect of hyperuricemia and overweight/obesity on the prevalence of hypertension among US

adults: result from the National Health and Nutrition Examination Survey. *J Hum Hypertens*. 2014;**28**(10):579–86. [PubMed ID: 24785975]. https://doi.org/10.1038/jhh.2014.31.
53. Valle M, Martos R, Canete MD, Valle R, van Donkelaar EL, Bermudo F, et al. Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children. *Pediatr Diabetes*. 2015;**16**(6):441–7. [PubMed ID: 25131560]. https://doi.org/10.1111/pedi.12199.
54. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol*. 2012;**176**(2):108–16. [PubMed ID: 22753829]. https://doi.org/10.1093/aje/kws002.
55. Cardoso AS, Gonzaga NC, Medeiros CCM, de Carvalho DF. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. *Jornal de Pediatria (Versão em Português)*. 2013;**89**(4):412–8. https://doi.org/10.1016/j.jpedp.2012.12.011.
56. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol*. 2013;**25**(2):210–6. [PubMed ID: 23370374]. https://doi.org/10.1097/BOR.0b013e32835d951e.
57. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric acid as a cause of the metabolic syndrome. *Contrib Nephrol*. 2018;**192**:88–102. [PubMed ID: 29393133]. https://doi.org/10.1159/000484283.
58. Kumar J, Gupta A, Dev K, Kumar S, Kataria D, Gul A, et al. Prevalence and causes of hyperuricemia in children. *Cureus*. 2021. https://doi.org/10.7759/cureus.15307.
59. Pastucha D, Talafa V, Malincikova J, Cihalik C, Hyjanek J, Horakova D, et al. Obesity, hypertension and insulin resistance in childhood–a pilot study. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2010;**154**(1):77–81. [PubMed ID: 20445714]. https://doi.org/10.5507/bp.2010.013.
60. Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, et al. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. *Am J Hypertens*. 2007;**20**(8):875–82. [PubMed ID: 17679036]. https://doi.org/10.1016/j.amjhyper.2007.03.005.
61. da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: Metabolic syndrome revisited. *Can J Cardiol*. 2020;**36**(5):671–82. [PubMed ID: 32389340]. [PubMed Central ID: PMC7219403]. https://doi.org/10.1016/j.cjca.2020.02.066.
62. Galipeau DM, Yao L, McNeill JH. Relationship among hyperinsulinemia, insulin resistance, and hypertension is dependent on sex. *Am J Physiol Heart Circ Physiol*. 2002;**283**(2):H562–7. [PubMed ID: 12124202]. https://doi.org/10.1152/ajpheart.00238.2002.
63. Takizawa H, Ura N, Saitoh S, Wang L, Higashiura K, Takagi S, et al. Gender difference in the relationships among hyperleptinemia, hyperinsulinemia, and hypertension. *Clin Exp Hypertens*. 2001;**23**(4):357–68. [PubMed ID: 11349826]. https://doi.org/10.1081/ceh-100102673.